Literature DB >> 11166514

Functional consequences of repeated (+/-)3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys.

M A Taffe1, M R Weed, S Davis, S Huitrón-Resendiz, R Schroeder, L H Parsons, S J Henriksen, L H Gold.   

Abstract

Six rhesus monkeys were trained to stable performance on neuropsychological tests of memory, reinforcer efficacy, reaction time and bimanual motor coordination. Three monkeys were then exposed to a high-dose, short course regimen of (+/-)3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") (4 days, 10 mg/kg i.m., b.i.d.). Following treatment, concentrations of 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) were reduced by approximately 50% in the treated animals, and this effect persisted for approximately three months post-MDMA. Behavioral performance was disrupted during acute MDMA treatment but returned to baseline within one week following treatment. MDMA also produced persistent alterations in late peak latencies of brainstem auditory evoked potentials (BSAEP), lasting three months post-MDMA. Both CSF 5-HIAA concentrations and evoked potential latencies were normalized four months after treatment. These findings indicate that serotonergic alterations associated with MDMA use may result in persisting changes in brain function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166514     DOI: 10.1016/S0893-133X(00)00185-8

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  18 in total

1.  3,4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory.

Authors:  Jessica A Able; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  Biol Psychiatry       Date:  2005-12-01       Impact factor: 13.382

2.  'Ecstasy' enhances noise-induced hearing loss.

Authors:  Michael W Church; Jinsheng S Zhang; Megan M Langford; Shane A Perrine
Journal:  Hear Res       Date:  2013-05-25       Impact factor: 3.208

3.  Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.

Authors:  R D Crean; S A Davis; S N Von Huben; C C Lay; S N Katner; M A Taffe
Journal:  Neuroscience       Date:  2006-07-28       Impact factor: 3.590

Review 4.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

5.  Effects of prior cocaine self-administration on cognitive performance in female cynomolgus monkeys.

Authors:  Sarah A Kromrey; Robert W Gould; Michael A Nader; Paul W Czoty
Journal:  Psychopharmacology (Berl)       Date:  2015-01-31       Impact factor: 4.530

6.  Impact of ambient temperature on hyperthermia induced by (+/-)3,4-methylenedioxymethamphetamine in rhesus macaques.

Authors:  Stefani N Von Huben; Christopher C Lay; Rebecca D Crean; Sophia A Davis; Simon N Katner; Michael A Taffe
Journal:  Neuropsychopharmacology       Date:  2006-04-12       Impact factor: 7.853

7.  Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys.

Authors:  Michael A Taffe; Christopher C Lay; Stefani N Von Huben; Sophia A Davis; Rebecca D Crean; Simon N Katner
Journal:  Drug Alcohol Depend       Date:  2005-11-11       Impact factor: 4.492

8.  Ketamine impairs multiple cognitive domains in rhesus monkeys.

Authors:  Michael A Taffe; Sophia A Davis; Tannia Gutierrez; Lisa H Gold
Journal:  Drug Alcohol Depend       Date:  2002-10-01       Impact factor: 4.492

9.  Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.

Authors:  Krista Lisdahl Medina; Paula K Shear
Journal:  Drug Alcohol Depend       Date:  2006-10-30       Impact factor: 4.492

10.  Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques.

Authors:  Rebecca D Crean; Sophia A Davis; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2007-04-03       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.